ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RVMD Revolution Medicines Inc

44.39
0.46 (1.05%)
24 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Revolution Medicines Inc NASDAQ:RVMD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.46 1.05% 44.39 42.00 54.00 44.42 43.49 44.00 350,019 22:00:00

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

27/11/2024 9:05pm

GlobeNewswire Inc.


Revolution Medicines (NASDAQ:RVMD)
Historical Stock Chart


From Dec 2024 to Dec 2024

Click Here for more Revolution Medicines Charts.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio.

The webcast will take place at 8:00 a.m. Eastern Time on Monday, December 2, 2024. To access the webcast, click here. An archived replay will be available on the “Events & Presentations” page of the Revolution Medicines website at https://ir.revmed.com/events-and-presentations for at least 14 days following the live event.

About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.

Media & Investor Contacts:
media@revmed.com
investors@revmed.com

1 Year Revolution Medicines Chart

1 Year Revolution Medicines Chart

1 Month Revolution Medicines Chart

1 Month Revolution Medicines Chart

Your Recent History

Delayed Upgrade Clock